文献速递湿疹皮炎与荨麻疹

阻断IL-13信号改善中重度特应性皮炎皮肤屏障功能与生物学

Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate-to-severe atopic dermatitis.
PubMed 文献 · Br J Dermatol · 2024-01-01

本研究评估tralokinumab(抗IL-13单抗)对16例中重度特应性皮炎患者皮肤屏障功能的影响,治疗16周。结果显示目标皮损平均TEWL下降33%(P=0.01),SCH增加58%(P=0.004),海绵水肿、角蛋白16表达和表皮厚度显著减少,屏障功能障碍相关蛋白和炎症蛋白显著下降,总细菌负荷和金黄色葡萄球菌丰度自第2周显著降低。

要点

  • tralokinumab治疗16周显著改善AD患者皮肤屏障功能,TEWL降33%、SCH升58%。
  • 治疗还改善表皮病理(海绵水肿、角蛋白16、表皮厚度)和皮肤微生态失调。
  • 屏障功能障碍相关蛋白和炎症蛋白显著下降,最早第8周可见变化。

核心结论

  • tralokinumab治疗改善了皮肤生理、表皮病理和微生态失调,进一步突显IL-13在AD发病中的多效性作用。

研究设计与样本

  • 对16例中重度特应性皮炎患者进行16周tralokinumab治疗,评估皮损、非皮损和月桂基硫酸钠刺激皮肤的TEWL、SCH、天然保湿因子含量、组织病理学特征、生物标志物表达和微生物组组成。

主要发现

  • 所有临床严重度评分随时间显著下降。
  • 第16周目标皮损平均TEWL下降33%(P=0.01),SCH增加58%(P=0.004)。
  • 组织学上海绵水肿减少(P=0.003),角蛋白16表达和表皮厚度减少(P=0.001)。
  • 纤连蛋白(P=0.006)、CCL17/TARC(P=0.03)和IL-8(P=0.01)等屏障功能障碍相关和促炎蛋白显著下降,最早第8周可见显著变化。
  • 总细菌负荷和金黄色葡萄球菌丰度自第2周显著降低。

临床怎么用

  • tralokinumab不仅改善AD临床严重度,还可改善皮肤屏障功能和微生态,支持其多效性治疗作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Interleukin (IL)-13 is a key driver of inflammation and barrier dysfunction in atopic dermatitis (AD). While there is robust evidence that tralokinumab - a monoclonal antibody that neutralizes IL-13 - reduces inflammation and clinical disease activity, less is known about its effects on barrier function. OBJECTIVES: To characterize the effects of tralokinumab treatment on skin barrier function. METHODS: Transepidermal water loss (TEWL), stratum corneum hydration (SCH), natural moisturizing factor content, histopathological characteristics, biomarker expression and microbiome composition were evaluated in lesional, nonlesional and sodium lauryl sulfate-irritated skin of 16 patients with AD over the course of 16 weeks of tralokinumab treatment. RESULTS: All clinical severity scores decreased significantly over time. At week 16, mean TEWL in target lesions decreased by 33% (P = 0.01) and SCH increased by 58% (P = 0.004), along with a histological reduction in spongiosis (P = 0.003), keratin 16 expression and epidermal thickness (P = 0.001). In parallel, there was a significant decrease in several barrier dysfunction-associated and proinflammatory proteins such as fibronectin (P = 0.006), CCL17/TARC (P = 0.03) and IL-8 (P = 0.01), with significant changes seen as early as week 8. Total bacterial load and Staphylococcus aureus abundance were significantly reduced from week 2. CONCLUSIONS: Tralokinumab treatment improved skin physiology, epidermal pathology and dysbiosis, further highlighting the pleiotropic role of IL-13 in AD pathogenesis. Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized by a marked skin barrier impairment. The skin barrier deficiency is characterized by an imbalance of organisms naturally found on the skin, including a reduction in the diversity of organisms and an increased amount of bacteria called Staphylococcus aureus. Further, there are reduced structural proteins, problems with ‘tight junctions’ (which maintain skin integrity) and abnormalities in the make-up/organization of skin lipids. As a result, the skin cannot keep itself hydrated or moisturized, and there is an increased likelihood of ‘irritant contact dermatitis’ (for example, rashes, dry skin and itching). ‘Interleukin (IL)-13’ is a signalling protein found in the immune system that is increased in AD and causes inflammation. Tralokinumab is a drug that neutralizes IL-13 and reduces inflammation and the severity of AD; however, less is known about its effect on the skin barrier. This study aimed to investigate the effects of tralokinumab on skin barrier function by looking at levels of water loss, hydration, natural moisturizing factor content, histopathological characteristics (how it looks under a microscope), the expression of biomarkers (indicators of a particular condition) and composition of the microbiome (organisms living together) in the upper skin layer of 16 people with AD who were treated with tralokinumab for 16 weeks. We found that blocking IL-13 leads to a better skin barrier with less water loss and better hydration, as well as the normalization of skin bacteria. The skin was also less irritable, and its microscopic appearance was similar to normal skin after 16 weeks of treatment. Finally, the drug appeared to be effective and safe. Overall, our findings suggest that by neutralizing IL-13, tralokinumab could help to restore the skin barrier function of people with AD.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Sander N, Stölzl D, Fonfara M, et al. Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate-to-severe atopic dermatitis. Br J Dermatol. 2024. PMID: 38531691. doi:10.1093/bjd/ljae138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。